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Abstract
The insulin (INS) region is the second most important locus associated with Type 1 Diabetes (T1D). The study of the DNA
methylation pattern of the 7 CpGs proximal to the TSS in the INS gene promoter revealed that T1D patients have a lower
level of methylation of CpG -19, -135 and -234 (p = 2.10216) and a higher methylation of CpG -180 than controls, while
methylation was comparable for CpG -69, -102, -206. The magnitude of the hypomethylation relative to a control
population was 8–15% of the corresponding levels in controls and was correlated in CpGs -19 and -135 (r = 0.77) and CpG -
135 and -234 (r = 0.65). 70/485 (14%) of T1D patients had a simultaneous decrease in methylation of CpG -19, -135, -234
versus none in 317 controls. CpG methylation did not correlate with glycated hemoglobin or with T1D duration. The
methylation of CpG -69, -102, -180, -206, but not CpG -19, -135, -234 was strongly influenced by the cis-genotype at rs689, a
SNP known to show a strong association with T1D. We hypothesize that part of this genetic association could in fact be
mediated at the statistical and functional level by the underlying changes in neighboring CpG methylation. Our observation
of a CpG-specific, locus-specific methylation pattern, although it can provide an epigenetic biomarker of a multifactorial
disease, does not indicate whether the reported epigenetic pattern preexists or follows the establishment of T1D. To
explore the effect of chronic hyperglycemia on CpG methylation, we studied non obese patients with type 2 diabetes (T2D)
who were found to have decreased CpG-19 methylation versus age-matched controls, similar to T1D (p = 2.1026) but
increased CpG-234 methylation (p = 5.1028), the opposite of T1D. The causality and natural history of the different
epigenetic changes associated with T1D or T2D remain to be determined.
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Introduction
Type 1 diabetes (T1D) results from the autoimmune destruction
of insulin-producing beta-cells caused by yet unknown environ-
mental factors in genetically predisposed individuals. While the
complexity of T1D causality is yet to be unraveled at the biological
and epidemiological levels [1], epigenetics can be suspected to
contribute to T1D causality as a reflect of environment-gene
interactions.
The current study focuses on the insulin (INS) locus. The genetic
polymorphism of DNA sequence at the INS locus has been
associated with T1D as the first application of the TDT
(Transmission Disequilibrium Test) approach to multifactorial
disease genetics [2]. Since then, it has been consistently confirmed
that T1D is associated [3,4,5,6] with the A/T SNP called rs689
and located at position +215 bp of the INS gene TSS. The MHC
locus being IDDM1, the INS locus was named IDDM2, because it
has the second highest odds ratio (OR) for T1D risk [7]. In
Caucasians, rs689 is in complete linkage disequilibrium (LD) with
the VNTR classes, allele A being associated with short class I
VNTR alleles, more frequent in T1D, while allele T is associated
with long class III alleles. Studies of INS gene expression suggested
that while given class I alleles are associated with increased INS
expression in a rodent ß cell line [8] and human pancreas [9]
versus class III alleles, the opposite observation was obtained in
whole thymic tissue [9,10]. Since rs689 did not seem to have per se
a functional role in the regulation of INS gene transcription, it was
proposed that sequence variation at the INS locus could affect INS
gene transcription through a tissue-specific functional difference
between VNTR classes. Possibly, epigenetic variation at the INS
locus could provide an interface between the predisposing rs689
SNP and variation in INS gene transcription. This is because in
mammals including humans, the DNA methylation of gene
promoter regions is known to play a role in the transcriptional
regulation of many genes, most often in a tissue specific manner
[11]. This was shown specifically for the INS locus where CpG
methylation of the promoter was able to modify gene expression in
b cell lines and islets of T2D patients [12,13]. The variation of
DNA methylation within the INS gene promoter, a low-CpG
containing region, may thus be suspected to regulate INS gene
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transcription in pancreatic ß cells and medullary thymic epithelial
cells (mTEC), the two tissues that express this gene and are central
to the mechanisms of T1D [14]. Since these tissues cannot be
studied in T1D patients, we undertook the study of DNA
methylation at the INS locus in whole blood cells (WBC) as a
possible surrogate of epigenetic marks in INS expressing tissues
[15].
To explore if chronic hyperglycemia could be suspected to cause
the observed changes in the methylation pattern of the INS
promoter, we studied a group of T2D patients compared with age-
matched controls.
Results
Using a bisulfite-PCR method [16], we measured DNA
methylation of 7 CpGs located in the proximal part of the INS
promoter in 485 T1D patients compared with 317 age-matched
non diabetic individuals (Table 1).
Association of CpG methylation at the INS locus with T1D
The CpG methylation pattern of the proximal part of the INS
gene promoter showed distinctive characteristics in the T1D
patients. First, there was no T1D-related global directional change
in methylation level that would affect all CpGs equally, nor did
neighbouring CpGs adopt systematically the same changes in
methylation. Compared with controls, CpGs -19, 2135 and 2234
in T1D patients showed a decrease in methylation (ranging from
210 to 216% of the mean, p,2.10216), while methylation of
other CpGs was either unchanged (CpGs -69, 2102, 2206) or
slightly increased (CpG -180, +3% of the mean, p = 1.1026)
(Table 2, Figure 1). Defining relative hypomethylation of a given
CpG as a value below 22SD of the corresponding control level,
we found that 70/485 (14%) T1D patients had a simultaneous
hypomethylation of CpG -19, -135 and -234, while 0/317 controls
showed such triple hypomethylation (p,2.10216). Methylation
levels of the four T1D-associated CpGs, although not in
immediate vicinity on the DNA phase, were closely correlated
(0.40,r,0.77, p,2.10216, Figure 2), suggesting a shared process
of regulation of the methylation status of these CpG residues, that
is also seen in controls. Methylation levels of other CpGs showed a
weaker degree of correlation between them as well as with the
T1D associated CpGs (Figure 2).
Age-dependency and stability of DNA methylation in
T1D patients
We found no correlation of methylation with T1D duration. We
did not find either any trend of correlation with glycated
haemoglobin (HbA1c), which reflects the degree of hyperglycemia
to which patients WBC are chronically exposed (data not shown).
We detected only a small trend of correlation of CpG -180
methylation with age (Figure 3). This may be due to the studied
range of ages, which extends only from 1 to 30 years, but we know
from analyses in older adult non diabetic subjects of another
cohorts that there is a downward age-dependent trend of
methylation for all CpGs located in INS promoter (Figure S1).
T1D patients who were studied twice at 1 month to 5 years
intervals, had consistent methylation values at all CpGs. Again,
none of the studied CpGs showed any correlation with intra-
individual changes in glycated hemoglobin values (Data not
shown).
Influence of rs689 genotype upon CG methylation at the
INS locus
We found a strong and consistent correlation between the
methylation status of 4/7 CpGs and the rs689 genotype (Figures 4
and 5), indicating that the T1D-predisposing A allele is
consistently associated with higher methylation levels of CpGs -
69, -102, -180, -206 (Figure 5). Note that CpG -180 hypermethy-
lation is associated with T1D. Not all rs689 neighboring CpGs
showed a dependency on this SNP, since rs689 had very little
influence on methylation values of CpGs -19, 2135, 2234, the
three other CpGs whose hypomethylation was found to be
strongly associated with T1D. A comparable genotype-epigen-
otype relationship was also observed for rs3842748, a SNP in high
linkage disequilibrium with VNTR classes as rs689, but almost
disappeared for the more distant SNPs rs4320932 and rs6356
located on either side of the INS locus (Figures 4 and 6). The
distribution of genotypes was not different in the patients having a
decreased methylation of the 3 CpG -19, -135, -234.
Association of CpG methylation at the INS locus with T2D
Compared with age-matched controls, T2D patients showed a
decrease in methylation at CpG -19, and an increase at CpG -234,
while methylation of other CpGs showed no or marginal (CpG-
102) changes (Table 3). There was no correlation between CpG-19
and CpG-234 changes in the T2D patients. Neither CpG-19
decrease nor CpG-234 increase in methylation were related to
T2D duration. None of the T2D patients showed a simultaneous
hypomethylation at CpG -19, -135, and -234, the distinctive
pattern observed in T1D patients.
Discussion
The current study investigated the DNA methylation pattern of
the INS promoter because the common genetic variation at rs689
is known to be strongly associated to T1D, and because no clear
functional role could be attributed to this SNP [2,3,4,5,6]. Among
the 7 CpGs located within the proximal INS promoter, we found
consistent methylation differences between T1D patients and non-
diabetic controls at 4/7 CpGs. These 4 CpGs were located 219,
2135, 2180 and 2234 bp from the TSS. Methylation at the
other 3 neighboring CpGs showed no difference between T1D
patients and age-matched controls. The small magnitude of the
differences observed at CpGs -19, -135, -180, -234 is consistent
with those reported recently by Rakyan et al in T1D twins studied
with a methylation array [17]. By combining the changes in
methylation at CpG -19, -135, and -234, it becomes possible to
Table 1. Main characteristics of T1D patients and age-
matched non diabetic controls.
T1D Patients T1D Controls
N 485 317
Sex (M/F) 259/226 163/153
Current age (yrs) 12.164.9 11.864.8
BMI (kg/m2) 18.463.2 23.3610.6
Age at clinical onset (yrs) 6.363.1 -
Diabetes Duration 7.568.5 -
Hba1c 8.161.4 -
Results are expressed as mean 6 sd.
doi:10.1371/journal.pone.0036278.t001
DNA Methylation and Type 1 Diabetes
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define a 3-CpG-hypomethylation pattern that seems to be present
only in T1D patients, thus could be specific and predictive of T1D,
if confirmed by follow-up studies. This 3-CpG pattern is present in
only 14% of T1D patients, thus is not sensitive as a biomarker.
We found surprising that T1D was associated with a gain of
methylation in one CpG (2180) and with a loss of methylation in
3 others, and we have no explanation for this observation. From a
general point of view, changes in DNA methylation, whether it is
an increase or a decrease for cis-located CpGs, may be related to
precisely located changes in the histone code and chromatin
structure, since there are well established interactions between
these epigenetic processes and DNA methylation [18]. If they
occur commonly, such discrepancies between neighboring CpG of
a given locus could be misleading in whole-methylome studies
since the methylation of the CpG used to tag the locus may not
reflect the methylation of other CpGs located at other positions
over the whole locus
Table 2. CpG methylation in the INS promoter in T1D patients and controls.
T1D Patients
(N=485)
CONTROLS
(N = 317)
T1D Patients
(n = 485)
CONTROLS
(n = 317)
DNA methylation (%) p Hypomethylated subjects N (%) p
CpG -19 54610 6466 ,2.10-16 190 (39%) 12 (4%) ,2.10216
CpG -69 9064 8966 0.65
CpG -102 7366 7369 0.11
CpG -135 5269 6865 ,2.10216 273 (56%) 12 (4%) ,2.10216
CpG -180 6967 66611 1.1026
CpG -206 9165 9167 0.62
CpG -234 5469 6266 ,2.10216 178 (37%) 8 (2%) ,2.10216
CpGs -19, -135, -180 5369 6466 ,2.10216 70 (14%) 0 ,2.10216
Results are expressed as mean6 sd. P-values are calculated by Wilcoxon rank sum test. Hypomethylated subject of a given CpG is defined by a methylation value below
-2SD of the corresponding control level. We have only shown, for clarity, the hypomethylated subjects in the right part of the table. In contrast, note that methylation of
CpG -180 is increased in T1D patients.
doi:10.1371/journal.pone.0036278.t002
Figure 1. Heatmap analysis of the relationship between DNA methylation of the whole proximal INS promoter and disease status.
Each row represents one individual.
doi:10.1371/journal.pone.0036278.g001
DNA Methylation and Type 1 Diabetes
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Another question encountered by epigenetic epidemiology is
whether the observed methylation changes pre-exist or follow the
establishment of the disease state. Since this cannot be inferred
from the current data, interpretation of the T1D associated
changes in DNA methylation should remain open to both
hypotheses. We are however encouraged to postulate that the
observed epigenetic pattern may contribute to T1D predisposition
or autoimmune mechanisms by the recent pioneering study of
Rakyan et al., who identified 132 T1D–associated methylation
variable positions in 15 T1D discordant MZ twin pairs [17]. This
latter approach did not detect the epigenetic pattern that we found
associated with T1D at the INS locus. This apparent discordance
can be explained by the methods used by these authors. A
difference is the greater statistical power of our case-control
approach compared to their twin study. While we used a
promoter-centered multi-CpG-per candidate region (7 CpGs
within 250 bp) approach, Rakyan et al. used a genome wide
one-CpG-per region approach. A following consequence of our
observation for the epigenetic epidemiology of T1D, but more
generally for the interpretation of epigenetic studies in multifac-
torial diseases, is that one CpG may not recapitulate the overall
methylation changes in a given genomic region. This may explain
why Rakyan et al. also using the CpG -180 as a unique marker of
the proximal promoter region have not observed a significant
association of this locus with T1D in the studied 15 twin pairs.
When methylation arrays bearing for example 27,000 CpGs
selected as markers among 28 millions CpGs on the human
genome, are used for methylome-wide approaches, these arrays
cannot encompass all CpGs of a given region. The high density
DNA methylation arrays (Infinium HumanMethylation450 [19]
and CHARM arrays [20]) and sequencing based technology,
should improve the coverage of the methylome. However, as
shown here, CpG residues in a given region may show variable
degrees of association between their level of methylation and the
disease, ranging from hypo- to hyper-methylation, and from
nonsignificant to highly significant levels of statistical association.
Thus it may be the heterogeneity of a methylation pattern that
turns out to be characteristic of a disease. To further explore if
exposure to chronic hyperglycemia could have resulted in the
observed changes of CpG methylation, rather than the T1D
disease itself, we studied a sample of non-obese patients with T2D
that had a somewhat comparable duration of exposure to
hyperglycemia. Comparison with age-matched controls revealed
that T2D patients share the hypomethylation of CpG-19 with
T1D patients, which could reflect a common consequence of the
hyperglycemic status. However T2D patients showed no consistent
trend for hypomethylation of CpG -135 or -234, a good marker of
T1D. Instead, the level of methylation was increased at CpG-135
(non significantly) and at CpG-234 (p = 5.1028). Again, the
causality of such changes in T2D escapes the limits of the current
report, and will be the matter of further investigation. Age
differences could not explain the discordance between T1D and
T2D patients. It is noteworthy that the two samples of controls also
showed differences in their methylation patterns at the INS locus,
as expected from an environmentally and age sensitive process.
Further investigations in other groups of T1D, T2D patients, and
age- and environmentally matched controls will be necessary to
explain these differences.
The current observations raise unresolved questions regarding
the functional meaning of the changes in the CpG methylation of
Figure 3. Lack of correlation between age and INS promoter methylation in T1D patients (green) and Controls (red). Only CpG -180
methylation showed a slight downward trend with age (r = 0.09, p = 0.01). The figure also shows the distribution of individual methylation values, and
the differences between T1D and control subjects for CpGs -19, -135, -180, and -234.
doi:10.1371/journal.pone.0036278.g003
Figure 2. Correlation matrix of the methylation values (%) at
the INS promoter CpG sites in T1D patients (R in bold, p-value
below). The T1D-associated hypomethylated CpGs -19, -135 and -234
are highly correlated (,10216).
doi:10.1371/journal.pone.0036278.g002
DNA Methylation and Type 1 Diabetes
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the INS promoter found in the WBC of patients with T1D. For
methylated CpGs to contribute to T1D mechanisms, methylation
changes modulating INS expression should have occurred in ß cells
and/or mTEC, according to our current view of T1D autoim-
mune pathogenesis. On the other side, if T1D pre-exist to the
changes in methylation, such changes in CpG methylation may be
caused by the metabolic perturbations related to the diabetic state.
Since WBC are exposed to numerous changes in plasma
composition in T1D patients, the DNA methylation at the INS
locus could be affected through a dysregulation of the methylation
machinery induced by T1D as an epigenetic signature of the
diabetic state. If this is the case however, it would be difficult to
understand the coexistence of increased and decreased CpG
methylation associated with T1D at different CpGs since one
would then expect the metabolic dysregulation to affect CpG
methylation in a consistent direction. Our T1D patients were
studied an average of 7.5 years after clinical diagnosis, a time when
ß cell destruction is expected to be largely terminated. Thus we do
not think that our observations in WBC interfere with those of
Akirav et al., who found an increased proportion of demethylated
DNA in the serum of 5 patients with recent-onset T1D, as a
possible index of active ß cell death [21].
We found that CpG methylation was influenced by the rs689
alleles known to be in strong LD with VNTR classes in Europeans
[22]. Genotype dependent variations of neighboring epigenotype
have been reported for the FTO locus in WBC [23] and for
several other loci across the genome (genome research) and called
ASM (Allele Specific DNA Methylation, see review [24]).
Shoemaker et al. observed ASM on 23% to 37% heterozygous
SNPs in several cell lines [25] while Zhang et al. evaluated that
ASM is likely to affect 10% of all human genes [26]. The finding of
a link between genetic variants and epigenomic marks in T1D
patients at the INS locus may provide a more general example of
how genetic and epigenetic variation can be related. This may
help our future understanding of the ‘‘missing heritability’’ enigma
seen with many genome wide association studies of multifactorial
traits or diseases, if it proves true that SNPs are only the markers
that tag neighboring epigenomic variations. According to this
view, certain SNPs showing strong statistical association with
complex diseases may not have any functional effects per se, but
Figure 4. UCSC Genome Browser map of the INS locus : localization of genes, CpG islands (CGI), variants and CpG sites. Genes are
represented by blue boxes (exons) and lines (intron). Under genes, CGI are in green. Green intensity and size of the box is function of the size and the
number of CpG included in CGI. Polymorphisms are represented by black boxes, under CGI. Below, a zoom of the INS promoter allowing the
localization and representation of the isolated CpG sites, according to the TSS, represented by the red arrow.
doi:10.1371/journal.pone.0036278.g004
Figure 5. Boxplot of methylation values of the studied CpGs in the INS promoter with respect to the rs689 genotype in T1D
patients. Except for the CpG -180, the T1D-associated CpGs show no direct association with the genotype. P-values are calculated by Kruskal-Wallis
test.
doi:10.1371/journal.pone.0036278.g005
DNA Methylation and Type 1 Diabetes
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may be associated with epitypes that have functional effects on
gene expression.
The CpG -180 is the only one that is both associated to T1D
and is influenced by the T1D-associated SNP rs689. The
hypermethylation of this CpG methylation has a marked influence
on INS gene transcription in vitro [12]. Indeed, Kuroda et al.
showed that methylation of the CpG -180, located in a cAMP
responsive element (CRE), suppressed INS promoter-driven
reporter gene activity by 50%. In human pancreatic islets, Yang
et al. also found that insulin mRNA expression correlated
negatively with the degree of methylation of CpG -180 [13]. If
such in vitro observations were to be true in the mTEC of T1D
patients, this would support that CpG -180 has a functional
contribution to the predisposing effect of rs689, a hypothesis
consistent with the increased methylation of this CpG in T1D
individuals carrying the A allele.
Decreased INS gene expression in the thymus of T1D patients
has been suspected to drive the defect of tolerance leading to
autoimmunity towards ß cells [9,10].
Whether epigenetic changes pre-exist or are a consequence of
T1D can only be established by long-term longitudinal studies of
DNA methylation in subjects at risk for the disease. Since it will a
priori remain almost impossible to investigate ß cells and mTEC in
T1D patients, the question of tissue-specific methylation changes
should have to be solved in animal models of T1D, like the NOD
mouse. It is possible that the observed pattern of CpG methylation
at the insulin locus may vary in other T1D and control populations
as a reflect of gene-environment interactions proper to these
populations. Until larger studies can be performed in such
populations, the observed variations in DNA methylation should
be considered restricted to the European people studied here.
Figure 6. Boxplot of methylation values for the 7 CpGs in INS promoter with respect to SNPs other than rs689 in T1D patients.
Methylation at CpGs -69, 2102, 2180 and 2206 are associated with rs3842748. More distant SNPs showed a much weaker correlation with
methylation at CpG -69 and -102 for rs4320932 and with methylation at CpGs -102, -135, -180 and2206 for rs6356. See Figure S1 for SNP locations. P-
values are calculated by Krukal-Wallis test.
doi:10.1371/journal.pone.0036278.g006
Table 3. CpG methylation in the INS promoter in T2D
patients and controls.
T2D Patients
(N = 132) T2D CONTROLS (N = 186)
DNA methylation (%) p
CpG -19 47611 54610 2.1026
CpG -69 88611 8866 0.22
CpG -102 68618 64613 0.01
CpG -135 58610 55610 0.06
CpG -180 57619 61611 0.14
CpG -206 91610 9367 0.79
CpG -234 5769 5166 5.1028
Results are expressed as mean 6 sd. P-values are calculated by Wilcoxon rank
sum test.
doi:10.1371/journal.pone.0036278.t003
DNA Methylation and Type 1 Diabetes
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Materials and Methods
Patients
Non-immortalized whole blood cell (WBC) samples were
obtained from 520 participants randomly extracted from the
Isis-Diab cohort (T1D cases) and from 317 controls. ISIS-Diab is
an ongoing prospective cohort of T1D patients recruited by a
French multicenter network composed of 77 diabetic centers (see
list in Table S1) supported by the Programme Hospitalier de
Recherche Clinique of the French Ministry of Health with the
objective of studying gene-environment factors in young patients
with T1D. To limit the risk of population stratification, all
recruited patients are of Caucasian ancestry assessed by family
history and grandparents’ birthplace. Inclusion criteria are
diabetes mellitus criteria, signs of insulin dependency, immediate
insulin treatment and presence of GAD autoantibodies in serum.
For the current study, we selected 317 Caucasian non diabetic
controls to be sex and age-matched with the T1D cases.
A sample of 132 non obese T2D patients aged less than 65
years, studied , 7 yrs after T2D diagnosis, as well as 186 age- and
BMI-matched controls, was obtained from UK to allow a
comparison with the young T1D patients analyzed in the current
study (Table S2).
Patients and controls were included in the study according to
the French bioethics law with families being carefully informed
and having signed a detailed informed consent agreed by CPP
(number DC-2008-693; NI 2620, Comite´ de Protection des
Personnes).
Isolation of genomic DNA and bisulfite genomic
conversion
Nucleic acids were extracted from WBC using the same phenol
chloroform technique in French T1D and controls and using the
same Promega DNA extraction kit in T2D patients and controls
from UK. Genomic DNA was treated with EZ-96 DNA
Methylation-Gold Kit, according to manufacturer’s protocol
(Zymo Research Corporation).
Pyrosequencing
We PCR-amplified the bisulfite treated genomic DNA using
unbiased nested primers (sequences on request) and performed
quantitative pyrosequencing. Pyrosequencing was performed using
a PyroMark Q96 ID Pyrosequencing instrument (Qiagen).
Pyrosequencing assays were designed using MethPrimer (http://
www.urogene.org/methprimer/index1.html). 200 ng of genomic
DNA was treated with EZ DNA Methylation-Gold Kit, according
manufacturer’s protocol (Zymo Research Corporation) and
amplified. Biotin-labeled single stranded amplicons were isolated
according to protocol using the Qiagen Pyromark Q96 Work
Station and underwent pyrosequencing with 0.5 mM primer. The
percent methylation for each of the CpGs within the target
sequence was calculated using PyroQ cpG Software (Qiagen).
Genotyping
Genotypes were obtained from GWAS data (Illumina Human-
Hap300_(v1.0.0), HumanHap300v2_A, HumanCNV370v1_C,
Human610-Quadv1_B). GWAS was conducted by the Centre
National de Genotypage (CNG, Evry, France).
Statistical analysis
Differences in DNA methylation of the insulin promoter
between T1D or T2D patients and non-diabetic controls were
analyzed using non-parametric Wilcoxon rank sum test. Correla-
tions were calculated as adjusted R square that measures the
proportion of the variation in the dependent variable accounted
for by the explanatory variables. Methylation data were clustered
using the heatmap.2 function of the R statistical computing
environment. Differences in DNA methylation of the INS
promoter according genotypes were analyzed using non-paramet-
ric Kruskal-Wallis test. Methylation analyses adjusted for age were
conducted using logistic regression. Results are expressed as mean
6 sd. ‘‘Relative hypomethylation’’ was defined as values of CpG
methylation under -2SD of the distribution of values in age-
matched controls of the same population of origin.
By default, the smallest p-value obtained by R is ,2.10216. All
statistical analysis were conducted using R 2.10.1.
Supporting Information
Figure S1 Correlation between age and INS promoter
methylation in two populations of controls, the young
controls used in the current T1D study (red) and a
cohort of older controls (black).
(TIF)
Table S1 List of the 77 diabetic centers by alphabetic
order participating to the ISIS-DIAB network.
(DOCX)
Table S2 Main characteristics of T1D patients and age-
matched non diabetic controls. Results are expressed as
mean ± sd.
(DOCX)
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